Tag: MASHNASH
Inventiva announces positive results from the proof-of-concept Phase II clinical trial, LEGEND, combining lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes – 03/18/2024 at 9:00 p.m.
Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…